CytoPharm

CytoPharm is a Taiwan-based biopharmaceutical company that focuses on the development, manufacturing, and commercialization of biologics, vaccines, and cell therapies. A member of the Orient EuroPharma (OEP) Group, the company is best known for its work on multi-subtype natural interferon and its Enterovirus 71 (EV71) vaccine candidate. CytoPharm operates a state-of-the-art PIC/S GMP-certified facility for biologics production, supporting its internal pipeline and providing contract manufacturing services. Its therapeutic focus primarily spans oncology and infectious diseases, with a growing emphasis on advanced cell-based immunotherapies. The company is listed on the Taiwan Emerging Stock Market and maintains strategic collaborations with national research institutes to drive innovation in the Asia-Pacific region.